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Abstract 
Background and aims: Esophageal adenocarcinoma (EAC) is chemoresistant in the majority of cases. 
The tumor-promoting biology of cancer associated fibroblasts (CAF) make them a target for novel 
therapies.   Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to regulate the activated 
fibroblast phenotype in benign disease.  We investigated the potential for CAF modulation in EAC 
using PDE5i to enhance the efficacy of chemotherapy.   
Methods: EAC fibroblasts were treated with PDE5i and phenotypic effects examined using 
immunoblotting, immunohistochemistry, gel contraction, transwell invasion, organotypics, single cell 
RNAseq and shotgun proteomics. The combination of PDE5i with standard-of-care chemotherapy 
(Epirubicin, 5-Fluorouracil and Cisplatin) was tested for safety and efficacy in validated near-patient 
model systems (3D tumor growth assays (3D-TGAs) and patient derived xenograft (PDX) mouse 
models).  
 Results: PDE5i treatment reduced α–SMA expression in CAFs by 50% (p<0.05), associated with a 
significant reduction in the ability of CAFs to contract collagen-1 gels and induce cancer cell invasion, 
(p<0.05). RNAseq and proteomic analysis of CAF and EAC cell lines revealed PDE5i specific regulation 
of pathways related to fibroblast activation and tumor promotion. 3D-TGA assays confirmed the 
importance of stromal cells to chemoresistance in EAC, which could be attenuated by PDE5i.   
Chemotherapy+PDE5i in PDX-bearing mice was safe and significantly reduced PDX tumor volume 
(p<0.05).   
Conclusion: PDE5 is a candidate for clinical trials to alter the fibroblast phenotype in esophageal 
cancer. We demonstrate the specificity of PDE5i for fibroblasts to prevent transdifferentiation and 
revert the CAF phenotype.  Finally, we confirm the efficacy of PDE5i in combination with 
chemotherapy in close-to-patient in vitro and in vivo PDX-based model systems.   
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Introduction 
Esophageal adenocarcinoma (EAC) is usually lethal. Most patients present with late stage disease 
and for those amenable to potentially curative treatments, 5-year survival is 50% at best.   
Randomised controlled trials (RCTs) confirm a survival advantage for neoadjuvant chemotherapy +/-
radiotherapy, but this benefit is restricted to a minority of patients.  For the majority, neoadjuvant 
treatments are ineffective, significantly morbid and delay definitive surgery
1-3
. 
Large-scale genome sequencing studies have detailed the genetic landscape of EAC and identified 
potential molecular targets.  These data reveal a highly complex tumor with driver gene mutations 
present in non-malignant precursor lesions that never progress to cancer, suggesting that drivers of 
disease development and progression may lie within the tumor microenvironment
4-7
. 
We have previously reported that activated cancer-associated fibroblasts (CAFs) influence outcome 
in EAC and the biological properties of esophageal CAFs that promote tumor progression
8, 9
.  CAFs 
have also been shown to influence the immune cell infiltrate and response to chemotherapy in a 
range of tumors
10-12
.   In general, the tumor-promoting properties of CAFs have been associated with 
the alpha-smooth muscle actin (α-SMA)-positive, activated, myofibroblast phenotype observed in 
cancer, fibrosis and wound healing
13-15
.  CAF targeting strategies have mostly focussed on the 
effectors of CAF tumor promotion including cell signalling and extracellular matrix molecules.  We 
have been working to understand how to target the CAF phenotype itself and whether new or 
existing drugs can be purposed for this use. 
Phosphodiesterase type 5 (PDE5) is part of a complex superfamily of hydrolases 
16
 that  control 
cAMP and cGMP levels by catalysing their breakdown. PDE5 is widely expressed in normal tissue and 
many human cancers, and its inhibition results in an upregulation of cGMP, which activates several 
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downstream pathways including protein kinase G (PKG) signalling.  Downstream substrates of PKG 
are implicated in a variety of biological processes such as smooth muscle contraction, cell 
differentiation, proliferation, adhesion and apoptosis
17, 18
.  The main function of PDE5 is to control 
vascular tone by regulating intracellular cGMP and calcium levels (Figure 1). 
Phosphodiesterase type 5 inhibitors (PDE5i) were first licensed to treat erectile dysfunction. More 
recently, high doses have been approved to treat pulmonary arterial hypertension and lower urinary 
tract symptoms
19-22
. New studies suggest repurposing PDE5i for treating conditions such as cancer or 
lung disease
18, 23
.  PDE5i have been found to attenuate the myofibroblast phenotype of prostatic 
fibroblasts, suggesting they could target the inflammatory/activated microenvironment observed in 
many solid tumors
24
.   
In EAC, we hypothesized that directly targeting the CAF phenotype with PDE5i would downregulate 
the tumor-promoting effects of CAFs and improve EAC sensitivity to conventional chemotherapy.  
This may improve outcomes for patients with EAC, of whom up to 80% do not respond to standard-
of-care neoadjuvant treatment
25
. Recent evidence has shown multimodal therapies of this type have 
acceptable tolerability and therapeutic potential
26-28
. 
In this study we characterized PDE5 expression in the human esophagus and described the effect of 
PDE5is on the tumor-promoting functions of esophageal CAFs in 2D and 3D models in vitro. We 
documented changes in CAF protein expression in response to PDE5i using shotgun proteomics and 
applied single cell RNA sequencing to demonstrate a phenotypic change in CAFs driven by co-culture 
with cancer cells and inhibited by PDE5i treatment.  Finally, we moved to a validated near-patient 
EAC model system to assess tolerability and efficacy of PDE5i in combination with standard-of-care 
chemotherapy.   
Materials and Methods 
 
Tissue and cell collection, maintenance and RNAi 
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Tissue was collected and stored with ethical agreement and informed consent (REC: 09/H0504/66 
and 18/NE/0234) at University Hospital Southampton, and fibroblasts were extracted from normal 
esophagus and esophageal adenocarcinoma and sub-cultured as previously described
29
.  siRNA-
mediated silencing of PDE5 was performed using INTERFERin transfection reagent and two 
commercially available siRNA sequences (detailed in supplementary methods). Endoscopic tumour 
biopsies (REC: 10/H0401/80) and fresh surgical specimens (REC: 08/H0403/37) were collected with 
informed consent from patients at Nottingham University Hospitals NHS Trust in 2014-15, and used 
in accordance with National Research Ethics Service approval to generate oesophageal cancer cell-
lines (detailed in supplementary methods) as previously described
30
.  
Immunohistochemistry 
Optimization and staining of cohort on full face sections using polyclonal rabbit anti-PDE5 (ab224232, 
abcam) was performed on a Dako link automated staining machine according to the manufacturer’s 
instructions. 
Western blotting  
Primary normal esophageal fibroblasts were treated under different conditions: ± TGF-β1, ± 
vardenafil (V-902, Sigma), and TGF-β1 + vardenafil; cancer associated fibroblasts were treated with 
vardenafil, or vehicle.  Cells were lysed and clarified after 72 hours.  For full details of antibodies 
used, experimental conditions and western blotting see supplementary methods. 
Immunofluorescence  
Immunofluorescence analyses were carried out as previously described
31
.   Primary antibodies: 
rabbit polyclonal anti-PDE5 (ab224232, abcam) and mouse monoclonal anti-α-SMA (M085129-2, 
Dako), Secondary antibodies: Alexa Fluor 568 donkey anti mouse IgG and Alexa Fluor 488 goat anti 
rabbit IgG (Molecular Probes). Cell nuclei were counterstained with 1 μg/ml DAPI (4’,6’-diamidino-2-
phenylindole).  
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Gel contraction 
Gel contraction assays were conducted as previously described
15
. Briefly, 0.5x10
6
 NOFs or CAFs (± 
TGF-β1, +/- 72 hours vardenafil treatment) were seeded in collagen-1 gels. Gels were photographed 
and weighed after 24 hours. 
Transwell invasion 
Transwell invasion assays were conducted as previously described
32
, using conditioned medium from 
NOFs or CAFs as the chemoattractant. NOFs and CAFs were cultured in the presence of TGF-β1 or 
TGF-β1 + vardenafil for 72 hours before washing out and collecting conditioned medium after 24 
hours.  FLO-1 cells were plated in the top chamber in identical numbers.  All experiments were 
repeated 3 times with 4 replicates per experiment.  Normalization was performed to the mean value 
of replicate 1 for all experimental conditions and data expressed as % invasion compared to the 
vehicle control. 
Organotypic cultures 
Organotypic cultures were carried out as previously described
29, 32
.  Briefly, CAFs were pre-treated 
with 50μM vardenafil or vehicle control for 72 hours before plating in 1:1 collagen:matrigel gels at a 
density of 5x10
5
 cells per gel, and the next day 5x10
5
 FLO-1 cells were cultured on top of the gels. 
Organotypic cultures were raised onto steel grids with overlaid nylon membrane supports and 
cultured at the air-liquid interface overnight before treatment. Organotypic cultures were incubated 
for a further ten days with added Vardenafil or vehicle control before processing.  Invasion was 
quantified and compared as previously described
33
. 
Proteomics 
Quantitative proteomics analysis 
Cells were treated with vardenafil, vehicle or PDE5 siRNA for 72 hours before trypsinisation and 
clarification.  Cells were lysed and protein extracts were quantified. One hundred ug of protein per 
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sample was reduced, alkylated and enzymatically digested using trypsin. Peptides were labelled 
using the isobaric tag for relative and absolute quantitation (iTRAQ) 8-plex reagents and analysed 
using two-dimensional liquid chromatography and tandem mass spectrometry as reported 
previously
34, 35
. For full details of downstream processing see supplementary methods. 
Droplet barcoded single cell RNA sequencing 
CAFs were grown in isolation or in co-culture MFD-1 cell line
36
. Cells were treated with vardenafil for 
72 hours before analysis.  This model was used to look at the transcriptional regulation of both 
cancer cells and CAFs in the presence of PDE5 inhibition.  
Cultured cells were trypsinized and resuspended in a cell suspension buffer and single cell RNA seq 
libraries created using DropSeq and then sequenced using Illumina NextSeq500. Single cell RNA-seq 
data was processed in R version 3.5.1 (Feather Spray) to cluster cells and perform differential gene 
expression analysis. For full details of downstream processing see supplementary methods. 
3D-tumor growth assay  
The individual patient’s epithelial cells were established, characterised, and then co-cultured in the 
3D-TGA +/- human mesenchymal stem cells (hMSC)
30
. Following exposure to drug combinations at 
human tissue-relevant concentrations, the cell viability was assessed using the alamarBlue® assay 
(ThermoFisher Scientific, Loughborough, UK). Viability curves were generated and IC
50
 values 
calculated using GraphPad Prism 5 software (San Diego, CA, USA). These were compared with the 
mean peak serum concentration achieved in patients for each chemotherapeutic agent to evaluate 
chemotherapeutic response as previously reported
30
. For full details see supplementary methods. 
Patient-derived xenograft models 
Patient-derived xenografts were developed using EAC biopsy specimens directly implanted into 
immuno-deficient mice as previously described
37
. Due to loss of the human stromal compartment in 
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such models, human mesenchymal stem cells (hMSCs) were co-implanted with the xenograft and 
supplemented before treatment began. Mice were treated with vehicle, Epirubicin, Cisplatin  and 
Capecitabine (ECX) or Cisplatin and Capecitabine (CX) alone or in combination  with vardenafil or 
tadalafil. For full details see supplementary methods. 
Statistical analysis 
Statistical analysis was performed with SPSS® version 19 (SPSS, Chicago, United States).  Patient 
survival was plotted using the Kaplan-Meier method and analyzed using the Log-rank test, with 
patients censored at last follow-up.  Multivariate Cox logistic regression was used to assess the 
relationship between α-SMA and pathological outcomes after resection.  Kruskal-Wallis, Mann 
Whitney U and T-tests were used to compare groups, as appropriate.  P < 0.05 was considered 
statistically significant (P < 0.05*, P <0.01**).  
Results 
Characterisation of PDE5 inhibitors in esophageal cancer 
To assess the suitability of PDE5 as a novel target in EAC we determined the expression of PDE5 in 
esophageal cancer cells and CAFs in primary resected tumor tissue and in extracted primary cells. 
PDE5 was highly and ubiquitously expressed in esophageal cancer tissue with low expression in 
normal tissue (Figure 2A).  In matched normal esophageal fibroblasts (NOFs) and CAFs, 2 commonly 
used EAC cell lines and a primary epithelial esophageal cancer cell line extracted in our laboratory 
(MFD-1)
36
, variable PDE5 expression was observed, determined by cell sub-type.  There was little or 
no PDE5 protein expression in the cancer cell lines with highest expression in CAFs (Figure 2B).  
Although a heterogeneous population, in general, CAFs are associated with a contractile and 
secretory phenotype characterized by increased expression of alpha-smooth muscle actin (αSMA). 
This activated, myofibroblastic state in cancer is believed to be driven by cancer cell signaling and 
can be recapitulated by treating normal fibroblasts with TGF-β1 in vitro.  We repeated our previous 
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experiments to confirm that NOFs treated with TGF-β1 significantly induced αSMA expression8, but 
when co-treated with vardenafil (a specific PDE5i) the increase in αSMA expression was abolished 
(Figure 2C).  Having established the potential of PDE5i to prevent NOF trans-differentiation in vitro 
we explored the possibility that PDE5i could suppress αSMA expression in CAFs.    After 72 hours of 
culture with vardenafil CAFs reduced αSMA expression by over 50% (p<0.01; Figure 2D).    The on-
target effects of PDE5i were confirmed by observing appropriate decreases in PDE5 and αSMA 
protein expression in response to PDE5 siRNA (Supplementary Figure S1).  Importantly for potential 
in vivo applications, we found that daily dosing of PDE5i produced significant αSMA downregulation 
compared to a single application of PDE5i-containing medium 72 hours before analysis 
(Supplementary Figure S2A).  After withdrawal of PDE5i, αSMA expression returned to pre-
treatment levels within 72 hours (Supplementary Figure S2B). 
PDE5 inhibition reduces fibroblast contraction and esophageal cancer cell invasion 
The expression of αSMA is characteristic of the myofibroblast phenotype but does not necessarily 
indicate functional capacity.  To test the hypothesis that PDE5i treatment of myofibroblasts could 
interfere with known tumor-promoting functions we performed a series of in vitro experiments to 
assess extracellular matrix contraction and the promotion of cancer cell invasion.  NOFs were 
embedded in collagen-1 gels after being treated with TGF-β1 alone or TGF-β1 + vardenafil.  
Fibroblasts that were treated with TGF-β1 significantly increased both αSMA expression and 
collagen-1 gel contraction, but after pretreatment with vardenafil the induction of αSMA and gel 
contraction was substantially and consistently reduced (Figure 3A).  CAFs express high levels of 
αSMA and induce collagen-1 gel contraction. Treatment with vardenafil significantly reduced αSMA 
expression and collagen-1 gel contraction in CAFs (Figure 3B).  Next, we assessed the ability of 
conditioned medium taken from fibroblast cultures to promote cancer cell invasion in transwell 
invasion assays under a variety of conditions.  The conditioned medium from TGF-β1-treated NOFs 
promoted 5 times more invasion of esophageal adenocarcinoma cells than conditioned medium 
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from vehicle-treated NOFs, whereas when vardenafil was added to TGF-β1 treatment of NOFs the 
resultant conditioned medium did not promote invasion (Figure 3C).  Similarly, vardenafil-treated 
CAF-conditioned medium induced significantly less cancer cell invasion than vehicle-treated CAF-
conditioned medium (Figure 3D). Similar observations were made using PDE5 siRNA (Supplementary 
Figure S1). This finding was reproduced in the more physiologically relevant organotypic co-culture 
model where we observed that vardenafil-treated CAFs had lost their ability to promote cancer cell 
invasion, compared to vehicle treated CAF (Figure 3E).  These findings suggested that, in vitro, PDE5i 
treatment was able to suppress both the transdifferentiation of NOFs and the tumor-promoting 
characteristics of CAF that we have previously observed
8
.  
Proteomic analysis of fibroblasts treated with vardenafil or PDE5 siRNA identifies modulation of 
major pathways associated with the cancer promotion. 
In keeping with previous reports in benign disease
24
 we established the ability of PDE5i to ameliorate 
some of the tumor-promoting functions of TGF-β1-driven, activated esophageal fibroblasts in vitro.  
To explore the cellular events responsible for these effects we took a whole-proteome based 
approach.  We have previously demonstrated the benefits of this approach to identify pathways and 
participating proteins that may provide novel insight into the tumor-promoting properties of CAFs
34
.  
Proteomic analysis was carried out on a NOF/CAF patient-matched pair.  The CAFs were treated with 
vehicle (negative control), vardenafil (PDE5i), PDE5 siRNA (positive control) and negative control 
siRNA and total protein expression assessed by quantitative proteomic profiling. To examine the 
effects of vardenafil or PDE5i siRNA treatment on the global proteomic profile of CAFs, we 
considered the following log2ratios: PDE5i vs. CAF vehicle, PDE5 siRNA vs. siRNA negative control 
and CAF vehicle vs. NOF. In total, 8118 proteins were quantified across all analysed samples (peptide 
level FDR < 0.05) (Supplementary Table x1). Principal component analysis of all quantified proteins 
showed that vardenafil treated CAFs clustered together with PDE5 siRNA treated CAF compared to 
vehicle treated CAF (Figure 4A). Since their global proteomic profile was similar, we considered 
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PDE5i vs. CAF vehicle and PDE5 siRNA vs. siRNA negative control as one group and performed a one-
sample T-Test to identify differentially expressed proteins (DEPs) following treatment with vardenafil 
or PDE5 siRNA. In total, 812 proteins were found to be up-regulated and 725 down-regulated in CAFs 
treated with vardenafil or PDE5 siRNA compared to their respective controls (Supplementary Table 
x2). In order to identify which of these proteins reflect the amelioration of the CAF phenotype 
following  vardenafil or PDE5 siRNA treatment, we compared the DEPs in CAFs treated with 
vardenafil or PDE5 siRNA to our previously published dataset of DEPs in CAFs vs. NOFs
34
. Using this 
approach, we identified 83 proteins that were down-regulated in CAFs vs. NOFs but became up-
regulated in CAFs following treatment with vardenafil or PDE5 siRNA (Figure 4B). Conversely, we 
identified 88 proteins that are up-regulated in CAFs vs. NOFs but became down-regulated in CAFs 
following treatment with vardenafil or PDE5 siRNA (Figure 4B) (Supplementary Table x3). We then 
performed gene ontology analysis for these 171 proteins that reversed their trend of modulation 
following treatment with vardenafil or PDE5 siRNA compared to CAFs. ECM organization (p = 0.01), 
ECM disassembly (p = 0.0008), sequestering of TGFβ in ECM (p = 0.0003), regulation of extracellular 
exosome assembly (p = 0.0005), cell-cell adhesion (p = 0.01), cell migration (p = 0.02), DNA damage 
response (p = 0.003), regulation of apoptosis (p < 0.0001), programmed cell death (p = 0.002), 
angiogenesis (p = 0.02), response to hypoxia (p = 0.02) and insulin receptor signaling pathway (p = 
0.006) were significantly over-represented GO terms (Figure 4C). These are all major pathways 
associated with the cancer-promoting properties of fibroblasts and identified in our previous studies 
of EAC fibroblasts
34
. To provide additional granularity, proteins exhibiting the most significant 
changes in expression in response to PDE5i treatment have been represented on a heatmap with the 
corresponding gene ontology term highlighted (Figure 4D). 
In summary, these findings suggest that vardenafil is specific for PDE5 inhibition in ex-vivo 
esophageal CAFs and leads to down-regulation of established cancer-promoting CAF pathways. 
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Single cell RNA sequencing reveals suppression of activated CAF phenotypes in MFD-1/CAF co-
cultures treated with a PDE5 inhibitor 
To this point, experiments had focused on understanding the specificity of PDE5i in prevention of 
fibroblast trans-differentiation and the functional/phenotypic effects of PDE5i on CAFs.  To be useful 
as a potential CAF-targeting treatment in cancer, these effects would need to be retained in the 
presence of cancer cells and be able to overcome any cancer cell-derived CAF-promoting signaling.  
To explore this, we took a single cell whole-transcriptomic approach using droplet-based 
microfluidics and single cell RNA sequencing (DropSeq) to analyse the gene expression of individual 
CAFs and esophageal cancer cells in direct co-culture
38
. CAFs were grown in isolation or in co-culture 
with esophageal cancer cell line, MFD-1 
36
. Cells were treated with vardenafil for 72 hours before 
analysis.  This model was used to look at the transcriptional regulation of both cancer cells and CAFs 
in the presence of PDE5 inhibition.  
Unsupervised clustering produced 2 broad clusters of cells, identified as either MFD1 (cancer cells) 
or CAFs, as defined by their transcriptomic profiles (Figure 5A).  Within these clusters a further 8 
sub-clusters were identified (Figure 5B). In general, the cells clustered based on their cell type and 
within those clusters on their culture conditions. 
In order to characterise the individual sub-clusters of cell phenotypes, differential gene expression 
analysis was performed using Seurat’s FindAllMarkers function with a log fold change cut-off of 1 
and otherwise default settings. Canonical marker genes differentially expressed between 
populations of CAFs (Thy-1/CD90, Decorin (DCN), Smooth Muscle Actin (ACTA2)) and MFD1s 
(Epithelial cell adhesion molecule (EpCam), Anterior gradient protein 2 homolog (AGR-2), Keratin-19 
(KRT19)) are shown in Figure 5C. 
The most striking finding from this experiment was the differential expression pattern of CAFs grown 
in different culture conditions. All CAFs from monoculture were similar in their transcriptomic profile 
to each other (Figure 5B, CAFp & CAFv). Importantly, the PDE5i-treated CAFs from monoculture 
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(CAFp) and co-culture (CAF.CoC.p) clustered together whereas the CAFs co-cultured with MFD1 in 
the absence of PDE5i formed a distinct cluster (Figure 5B, CAF.CoC.v). This cluster was markedly 
different to those from the monoculture with vehicle treatment and all other CAFs indicating a 
phenotypic change in CAFs driven by co-culture with cancer cells and inhibited by PDE5i treatment. 
The gene expression that defined the transcriptome of CAFs in co-culture is highlighted in Figure 5D.  
All are associated with the activated/myofibroblast phenotype of CAFs. This data demonstrates that 
CAFs adopt a myofibroblastic phenotype in co-culture with cancer cells in vitro and that this process 
can be inhibited by treatment with PDE5i, despite the presence of cancer cells, resulting in 
downregulation of myofibroblast genes such as ACTA2 (αSMA), myosin light chain kappa (MYLK), 
osteonectin (SPARC) and transgelin (TAGLN)(Figure 5D). 
 
Three-dimensional co-culture models of close-to-patient cancer cells and human mesenchymal 
stem cells reveals that PDE5 inhibition increases the efficacy of chemotherapy in EAC. 
The standard-of-care for locally advanced esophageal adenocarcinoma treatment includes 
neoadjuvant chemotherapy before resection.  Cancer is confirmed by pre-treatment biopsy and this 
tissue can be used to grow the patient’s cancer epithelial cells ex vivo
30
.  We have used cancer cells 
harvested at this time point, as well as matched cells established from post-neoadjuvant 
chemotherapy surgical specimens, to investigate the potential for PDE5i treatment to enhance the 
efficacy of standard-of-care chemotherapy (epirubicin, cisplatin and 5-FU; ECF).  Ex vivo cancer cells 
(confirmed by FACS) were grown with human mesenchymal stem cells (hMSC) in a 3D matrix to form 
a 3D-Tumor Growth Assay (3D-TGA) as previously described
30
 (Figure 6A,B).  We have previously 
shown the importance of the stromal compartment in 3D-TGA as the ex vivo drug response in the 
presence, but not absence, of mesenchymal cells accurately reflected clinical chemo-sensitivity, as 
measured by tumor regression grade (TRG)
30
.  
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Using the 3D-TGA we tested the effect of PDE5i on tumor cell chemo-sensitivity in combination with 
ECF chemotherapy using 15 samples from 8 different patients. We hypothesised that the addition of 
the PDE5i may affect the interaction of the stromal cells with the epithelial cancer cells within the 
3D-TGA, and may reduce the patient-specific ECF chemo-resistance demonstrated by these ex vivo 
3D co-culture models. When the 3D-TGA models of EAC were exposed to PDE5i alone, there was no 
chemo-toxic effect seen in any of the 15 models, with or without the hMSC stromal support. PDE5 
treatment did not have toxic effects on hMSCs when grown alone in the 3D-TGA (Supplementary 
material 3, Figure 1). 
Overall, the addition of PDE5i to ECF chemotherapy resulted in a significant decrease  in IC
50
 chemo-
resistance (p=0.0033) (Figure 6C).  This effect was not seen without hMSC stromal support 
(Supplementary material 3, Figure 2), indicating that PDE5i-enhanced chemo-sensitivity is a stromal-
mediated process. The individual patient stromal-mediated effect of PDE5i on ECF drug resistance 
was demonstrated in detail (Supplementary material 3, Figure 3, 4). 
A PDE5i-mediated reduction in chemo-resistance was found to be patient-specific (Figure 6D,E) with 
the size of the PDE5i chemo-sensitising effect varying between patients; there was a trend to 
reduction in IC
50
 seen in 12 of the 15 samples, and a statistically significant (CI >95%, p < 0.05 ) 
reduction in the IC
50
 chemo-resistance in 6 of these samples (Figure 6F).  
Overall, four of the eight patients studied had a PDE5i mediated significant reduction in ECF chemo-
resistance in at least one tumour sample. Five of the eight patients had chemo-resistant tumours, 
both ex vivo in the 3D-TGA and clinically (TRG 4 - 5). With addition of PDE5i to the ECF chemotherapy 
regimen three of these five patients had a significant reduction in the ex vivo IC
50
 to a magnitude 
similar or less than the mean peak serum concentration used in UK clinical practice, and thus 
suggesting that 60% of these ECF chemo-resistant tumours could become chemo-sensitive clinically 
with the adjunctive administration of PDE5i (Figure 6F).  
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PDE5i is safe and effective in combination with standard of care chemotherapy in esophageal 
patient-derived xenograft (PDX) bearing mice.  
Before considering a human trial of PDE5i in EAC we performed a dose-escalation study to assess 
potential serious toxicity of combining chemotherapy with PDE5i, and an efficacy study in a PDX 
mouse model supplemented with human stromal support.  The PDX was developed with esophageal 
cancer tissue taken from patient tumour sample Oes7R. This was chosen as it was resistant to 
chemotherapy clinically and in the 3D-TGA, but was responsive to adjunctive PDE5i.  Since human 
stroma is lost in PDX models over time, hMSCs were incorporated at passage to maintain a human 
stroma.  A dose escalation study was initially performed with Epirubicin, Cisplatin and Capecitabine 
(the oral equivalent of 5-FU) (ECX) in three non-tumor bearing mice. This revealed peak tolerable 
doses of ECX that were 50% of the human equivalent doses (Supplementary Figure S4).  Next, dose 
escalation studies for PDE5i were carried out in four groups of three PDX-bearing mice (no treatment, 
ECX alone, ECX+PDE5i (vardenafil), ECX+ PDE5i (tadalafil)). PDE5i dose increases were carried out in 
three phases in combination with a static dose of ECX (as previously determined).   No adverse side 
effects (e.g. weight loss or lowered threshold of ECX tolerability) were reported for maximum doses 
of either vardenafil or tadalafil. To confirm these findings, representative sections of native spleen, 
liver, aorta and heart were assessed and showed no gross morphological differences between 
groups (Supplementary Figure S5), suggesting no deleterious effects with the addition of PDE5i.   
In the efficacy study, a significant reduction in tumour volume was observed in the CX, CX+Vardenafil 
and CX+Tadalafil (Two-way ANOVA, p-values of 0.003, <0.0001, and 0.007 respectively) with the 
biggest reduction in tumour volume in the CX+Vardenafil group. Comparison of the tumour volume 
in the 4 groups on the final day of the study revealed that only the CX+Vardenafil group was 
significantly reduced compared to vehicle control (Kruskal Wallis test, p=0.04), demonstrating the 
stronger effect of CX+Vardenafil compared to CX treatment alone or CX+Tadalafil. 
Discussion 
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Stromal remodeling can promote cancer progression. CAFs display an activated myofibroblast 
phenotype and expression of αSMA in many solid tumors is a marker of reduced disease free and 
overall survival
8, 35, 39-41
.  The tumor-promoting biology of CAFs make them a target for novel cancer 
therapies.  In this study, we have demonstrated that PDE5 is a potential new target for altering the 
fibroblast phenotype in EAC.  Using a combination of conventional in vitro molecular biology 
techniques, state-of-the-art proteomic and single cell sequencing technologies we have documented 
the specificity of PDE5i for fibroblasts both to prevent transdifferentiation and revert the activated 
myofibroblast (CAF) phenotype.  Finally, in a step towards a clinical trial we have confirmed the 
efficacy of PDE5i in combination with chemotherapy in close-to-patient in vitro and in vivo PDX-
based model systems.   
This study is not without shortcomings.  Some of the in vitro work has been performed with cell lines 
that may not represent the true in vivo biology of these cell types. We supplemented these findings 
with those of more representative close-to-patient in vitro models which more accurately reflect the 
response of EAC cells to chemotherapy. Our proteomic analysis was conducted with a single, 
representative NOF/CAF pair, and further validation of these findings might be sensible.  Finally, we 
have not tested PDE5i efficacy in a spontaneous EAC animal model.  Unfortunately, no good model 
of EAC exists, meaning that the best testing-ground for PDE5i in EAC will be in humans.  To mitigate 
this, we have used a validated near-patient PDX model to demonstrate efficacy. 
Our findings are in keeping with many reports documenting the role of fibroblasts in cancer. 
Activated myofibroblasts are contractile and pro-invasive in EAC models
8
.  There is evidence that 
CAFs can protect cancer cells from chemotherapy
42
, create an immunosuppressive environment, 
reduce the immune infiltrate and alter the immune composition allowing cancer cells to escape 
immune surveillance
43-45
.  By reducing the trans-differentiation of fibroblasts in cancer and by 
modulating the phenotype of activated CAFs we may be able to improve overall survival by several 
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different mechanisms: improving response to chemo/immuno-therapy, increasing tumor cell 
recognition by the immune system and reducing cancer cell invasion.   
Several strategies have been proposed to target pro-tumorigenic CAF functions, mostly through 
modulating the effectors of the CAF phenotype rather than the cell state itself.  These include 
targeting the ECM remodeling enzymes such as the lysyl oxidase family and MMPs, or targeting CAF-
derived molecular signals (e.g. CXCR4, TGF-B, HGF) (reviewed in 
9
). 
Initial attempts to specifically target CAFs have centered on the membrane bound glycoprotein 
Fibroblast Activation Protein alpha (FAP). Early promise with FAP-targeting monoclonal antibodies 
has not translated into clinical success (reviewed in
46
). Novel mechanisms to prevent myofibroblast 
differentiation and CAF accumulation are now required. PDE5i might offer a compelling way forward 
for this purpose.  Importantly, PDE5i are a safe and well tolerated class of drug administered to 
millions of patients world-wide to treat erectile dysfunction, benign lower urinary tract symptoms 
and pulmonary arterial hypertension
21, 47
. High dose PDE5i show safety and efficacy for treating 
heart failure with reduced ejection fraction
48
. There is a significant body of evidence supporting 
PDE5i use in treating a range of cancers (reviewed in 
18
).  In particular, animal studies suggest PDE5i 
have potent immunomodulatory activity that warrants clinical study with or without immune check-
point inhibition
49
. PDE5i are currently being tested in combination with standard-of-care and other 
novel treatments in a range of cancer types including gliomas, head and neck squamous cell cancer, 
pancreatic cancer and malignant melanoma
18
. With this background, the sensible next steps for 
testing PDE5i in EAC are in the context of a phase I/II human clinical trial.  
In summary, we provide in vitro, near-patient and in vivo evidence for the potential role of PDE5i in 
treating esophageal adenocarcinoma and suggest a rationale for future human trials. 
Figure legends 
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Figure 1. The involvement of PDE5 in the NO/cGMP/PKG pathway. Nitric oxide produced by 
endothelial cells activates guanylate cyclase in smooth muscle and stimulates cGMP production. 
cGMP activates downstream signals including protein kinase G family proteins. Targets of PKG in 
turn stimulate smooth muscle relaxation. VASP is also a major target of PKGs, and regulates cell 
adhesion and motility. 
Figure 2. A. PDE5 expression analysed by IHC of normal esophagus and esophageal adenocarcinoma. 
PDE5 expression is highest in but not confined to the stromal tissue. B. Western blot and ICC for 
PDE5 expression in three cancer cell lines and five matched normal (NOF)/cancer (CAF) primary 
esophageal fibroblasts. C. NOFs treated with TGF-β1, +/- 50μM vardenafil for 72 hours. TGF-β1 
treated NOFs express higher α-SMA, vardenafil pre-treatment abrogated the TGF-β1 induced 
expression of α-SMA. D. CAFs treated with 50μM vardenafil for 72 hours reduced α-SMA expression 
by 50% by western blot and ICC. 
Figure 3. A. Fibroblast contraction analysed by normal esophageal fibroblasts (NOFs) treated with 
TGF-β1 ± 50μM vardenafil embedded in collagen-1 gel. TGF-β1 treatment induced αSMA expression 
and gel contraction in normal fibroblasts, co-treatment with vardenafil inhibited the upregulation of 
αSMA and reduced gel contraction by 50%. B. Cancer associated fibroblast (CAF) contraction was 
analysed by collagen-1 gel contraction, ± 50μM vardenafil.  αSMA expression and collagen-1 gel 
contraction is 2-fold greater in untreated CAFs compared to vardenafil treated CAFs. C,D Cancer cell 
invasion was analysed by transwell assays using conditioned medium from fibroblasts as the 
chemoattractant. C. Normal fibroblasts ± TGF-β1 ± vardenafil, TGF-β1 treated NOFs promoted 
invasion of FLO-1 cells with a 5-fold induction. This induction was abrogated by vardenafil treatment. 
D. CAFs treated with vardenafil reduced invasion of FLO-1 cells by 60%. E. Organotypic co-culture of 
FLO-1 cells and CAFs also showed inhibition of invasion when treated with vardenafil. 
Figure 4. Proteomics: A. Principal component analysis of all quantified proteins showed that 
vardenafil treated CAFs clustered together with PDE5 siRNA treated CAF compared to vehicle 
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treated CAF. B. Comparison of DEPs in CAFs treated with vardenafil or PDE5 siRNA with a previously 
published dataset of DEPs in CAFs vs. NOFs
34
, identified 83 proteins down-regulated in CAFs vs. NOFs 
but became up-regulated in CAFs following treatment with vardenafil or PDE5 siRNA. Conversely, 88 
proteins were up-regulated in CAFs vs. NOFs but became down-regulated in CAFs following 
treatment with vardenafil or PDE5 siRNA. C.  Gene ontology analysis using DAVID of the 171 proteins 
that reverse their trend of modulation following treatment with vardenafil or PDE5 siRNA compared 
to CAFs. D.  Proteins mapping to the respective GO terms. 
Figure 5. Droplet barcoded single cell RNA sequencing. A.  Cluster analysis of MFD-1 and primary 
CAFs based on differentially expressed genes from single cell RNA sequencing analysis.  Firstly cells 
were clustered as either cancer cells (MFD-1) (blue) or fibroblasts (red). B. Further cluster analysis 
showed CAFs treated with PDE5 inhibitor vardenafil (CAFp) clustered separately from vehicle-treated 
CAFs (CAFv). PDE5i-treated co-cultured CAFs clustered with all other CAF cultures, whereas vehicle-
treated CAF co-cultured with MFD-1 show a phenotypic shift and clustered separately. C. Violin plots 
showing typical gene expression profiles for fibroblasts (THY1, DCN, ACTA2) or epithelial cells (KRT8, 
KRT18, EPCAM) show good separation between the clusters in A. D. Heatmap shows the top 5 
differentially expressed genes between treatment groups. CAFs and MFD-1 cells have the most 
distinct gene expression profiles and although PDE5i treatment and co-culture both affect gene 
expression of both cell types, CAFs were most affected under both conditions. 
Figure 6.  Sensitivity of close-to-patient cells was determined in 3D-TGA, with and without 
mesenchymal cell co-culture, after 4 day exposure to ECF and Vardenafil (PDE5i) drug combinations. 
A. 3D-TGA workflow. B. Image of typical 3D-TGA co-cultured clusters of epithelial cells and mCherry 
labelled hMSC cells captured using condensed multilayer focussed fluorescent microscopy. C. 
Viability curves were generated and IC
50
 values determined. Overall sensitivity of all the EAC patient 
samples co-cultured with hMSCs was determined for assays with and without the addition of PDE5i 
to ECF chemotherapy. Horizontal lines represent mean IC
50
s. Representative patient responses to 
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PDE5i are shown: following the addition of PDE5i to the ECF chemotherapy there is a significant 
change in chemosensitivity for patient sample Oes5B D. but not for Oes5R E. Statistical significance is 
determined by the arithmetic variance between the calculated IC
50
s and their distinct 95% 
confidence intervals which have no overlap. F.  IC
50
s obtained for a cohort of EAC patients’ ECF-
treated 3D-TGAs, with (+) and without (-) hMSC support and the addition of PDE5i. The patient 
cancer cell clusters were classified as sensitive (green), borderline (orange), or resistant (red) by 
comparison of IC
50
 values to the mean peak serum concentrations achieved in patients at the doses 
used in UK clinical practice. This is marked ‘Y’ where the IC
50
 drop is significant (CI >95%, p <0.005). 
Tumour regression score (TRG) denotes the chemotherapy response of the patient’s tumour 
clinically (TRG1-3: sensitive; 4-5: non-responsive). 
Figure 7. Efficacy in an oesophageal PDX model. An efficacy study was carried out in mice bearing 
oesophageal PDXs supplemented with human MSCs.  Mice were treated with CX, CX+Vard, CX+Tad 
or vehicle alone.  Tumour volume was expressed as a percentage of the last tumour read before 
commencement of dosing for individual mice and shown as mean +/- standard error of each group.  
Supplementary Figure S1.  A. Western blot showing PDE5 siRNA knockdown in CAFs showing 
concomitant reduction in PDE5 and αSMA expression. B. Fibroblast contraction was assessed using 
CAFs ± PDE5 siRNA collagen-1 gel contraction assays.  Reduction in PDE5 expression reduced 
collagen-1 gel contraction in CAFs and (C) the induction of FLO-1 cell invasion.  
Supplementary Figure S2. A. Western blot and histogram assessing αSMA expression after 72 hours 
50μM vardenafil treatment. A 50 % reduction in expression was achieved with one treatment in 72 
hours, whereas treatment every 24 hours (3 treatments in a 72h period) significantly downregulated 
αSMA expression by 80%. B. Western blot assessing αSMA expression in different patient CAFs after 
the removal of vardenafil treatment. Both CAF populations underwent a significant reduction in 
αSMA, but comparison of the two CAF populations reveals differences in time to maximum 
inhibition and time to rebound levels of αSMA expression. 
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Supplementary Material S3. Further details on chemosensitivity findings in 3D-TGA cultures. 
Supplementary Figure S4. PDE5i dose escalation study in combination with ECX at 50% dosage in 
non-tumor-bearing mice. Immune-incompetent mice (n=3) tolerate ECX treatment at half the 
equivalent human dosage.  3 cycles of ECX were administered over 8 weeks. Cycle 1 was 25% 
equivalent dose; Cycle 2 was 50% equivalent dose; In cycle 3, two mice received 75% equivalent 
dose and one mouse received a repeat of cycle 2 due to rapid weight loss (50%). 
Supplementary Figure S5. Histological evaluation of PDX tumors and murine organs previously 
reported as being affected by ECX treatment. Hematoxylin & eosin stained sections of murine 
tissues from PDX-bearing mice in this study, treated with ECX alone or ECX with vardenafil or 
tadalafil. No gross histological changes were observed in mice treated with vardenafil or tadalafil 
compared to mice receiving ECX treatment alone. 
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